Revance is in the single digits because of the exact points you make. All the skin care trials are subjective and sadly the customer is the judge and jury.
The premium pricing seems to have been the big negative, not a lack of efficacy.
Efficacy in glabellar lines can be readily measured with photographs and videos. This is entirely different from an efficacy endpoint derived from a patient’s self-reported feeling in a migraine or depression trial.
Over the years, I’ve found posts that verbalize a feeling of hopelessness about a company’s prospects are a pretty good contrary indicator. What you’re saying about RVNC is what many people were saying about the stock market as a whole in Mar 2009, when I posted #msg-35980601.
I’m confident that this post will age as well as that one did.
Daxxify is the best botulinum toxin on the market, and it will take a long time for competitors to produce something as good, if they can do it at all. RVNC is destined to make a lot of money for shareholders, and the valuation will reflect this in due course.
The best time to buy shares is when nobody else wants them.
News 
Market Data 
Discover 
